

Supplementary Table 1. Baseline Disease Activity (MDA Components) in MDA Achievers and Non-Achievers at Week 24 by Randomized Treatment

MDA Component, mean (SD)	MDA Achievers		MDA Non-Achievers	
	Adalimumab (n=24)	Placebo (n=4)	Adalimumab (n=36)	Placebo (n=55)
TJC	17.5 (19.2)	10.5 (12.4)	29.3 (17.0)	29.4 (17.1)
SJC	11.4 (12.3)	7.8 (7.0)	18.0 (10.7)	17.4 (12.7)
Patient pain	43.3 (19.6)	20.8 (30.2)	56.2 (22.6)	47.6 (21.3)
PtGA	44.0 (25.3)	33.0 (33.9)	51.7 (23.3)	46.8 (21.7)
PASI	5.7 (3.0)	17.6 (15.8)	8.9 (7.3)	7.6 (5.7)
HAQ-DI	0.7 (0.6)	0.3 (0.5)	1.3 (0.6)	1.1 (0.7)
Enthesitis	0.4 (1.0)	0.0 (0)	1.0 (1.4)	1.0 (1.4)

HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI, Psoriasis Area and Severity Index; PtGA, Patient Global Assessment of disease activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints.